# SEG Drug HTML Review Status v1

**Document ID:** `SEG_DRUG_HTML_REVIEW_STATUS_v1`  
**Mode:** `CONTROLLED REVIEW EXECUTION`  
**Source:** Drug HTML  
**Review outcome:** `REVIEW_BLOCKED_PENDING_EVIDENCE`  
**Current source gate:** `BLOCKED_PENDING_EVIDENCE`  
**Operational state:** `INTERNAL_REFERENCE_ONLY` / `WAITING_FOR_EVIDENCE`

## 1. Review scope and exact artifact

This document records a read-only, evidence-based review preparation for the retained Drug HTML representation. The review target is the exact UTF-8 HTML artifact of 25,918 bytes and 394 lines with SHA-256 `5367711d08df2393cf852815b1b9d0ad4dac8240ac061cd88c71a53884e938ac`. The artifact includes an observed internal title signal referring to a Rosen/Tintinalli medication summary and 47 observed `drugList` entities. These are artifact observations only; they do not establish canonical source identity, medical correctness, or approval.[1]

No source text was corrected, rewritten, normalized, or converted into a content record during this preparation. No clinical conclusion was generated and no reviewer identity was assigned.

## 2. Review performed and evidence available

The review preparation checked the current artifact identity, the source-authority record, the version-control register, the audit-trail foundation, and the role-assignment matrix. The available evidence supports a retained artifact and limited structural observations. It does not provide an authoritative source edition, a complete provenance chain, independent rights evidence, or completed clinical/technical review.[1] [2] [3]

| Review preparation item | Evidence available | Status |
|---|---|---|
| Exact artifact identity | UTF-8 HTML, 25,918 bytes, 394 lines, SHA-256 recorded | `CONFIRMED` for retained representation |
| Observed structure | 47 `drugList` entities; no explicit interaction table observed in the prior artifact review | `PARTIALLY_CONFIRMED` as artifact observation only |
| Canonical source identity | Internal title signal only; no authoritative source record | `PARTIALLY_CONFIRMED` / unresolved |
| Source version and date | No edition, version, release, or publication date | `NOT_AVAILABLE` |
| Provenance | Local artifact origin and partial recovery continuity | `PARTIALLY_CONFIRMED` |
| Rights and license | No owner, license, educational-use, display, or redistribution evidence | `NOT_AVAILABLE` |
| Medical review | Required role is documented; no named reviewer, review event, or decision | `PENDING_REVIEW` |
| Technical review | HTML/JavaScript/lineage review required; no completed review | `PENDING_REVIEW` |

## 3. Clinical accuracy review requirements

An independent Emergency Medicine Reviewer must examine the exact retained artifact after the applicable source, version, locator, and provenance evidence is available. The review scope must cover the clinical content represented in the artifact, including indications, dose statements, contraindications, clinical context, currency, omissions, ambiguity, and conflicts. Any source-derived claim must be checked against the authoritative and versioned source evidence rather than the filename, title signal, or artifact structure alone.

This preparation does not determine whether any clinical statement is accurate, current, complete, safe, or suitable for learner use. It records the questions that the authorized reviewer must answer and requires exact section/entity locators, reviewer role and identity, review date, findings, conflicts, unresolved issues, and disposition in a future review record.

**Current clinical-review state:** `PENDING_REVIEW`; execution is `REVIEW_BLOCKED_PENDING_EVIDENCE`.

## 4. Drug-safety review requirements

A separate Pharmacology/Drug Safety Reviewer must independently examine the exact retained representation. The review must address drug identity, dose statements, interactions, contraindications, safety signals, omissions, ambiguity, and the boundaries of any interaction information represented by the artifact. The prior observation that no explicit interaction table was found is not a clinical conclusion and must not be treated as evidence that interactions are absent.

The reviewer must preserve any conflict or uncertainty and cite the exact artifact locations examined. The review must not silently correct the HTML, add missing medication facts, infer a current protocol, or convert the artifact into a validated drug reference.

**Current drug-safety review state:** `PENDING_REVIEW`; no named reviewer or conclusion is recorded.

## 5. Missing metadata and governance evidence

| Required metadata or evidence | Current status | Blocking effect |
|---|---|---|
| Canonical title and authoritative source | `NOT_AVAILABLE`; only an internal title signal is observed | Source identity remains open |
| Publisher, owner, author, or authorized custodian | `NOT_AVAILABLE` | Authority and rights attribution remain open |
| Edition, version, release, and publication date | `NOT_AVAILABLE` | Version-controlled clinical review cannot close |
| Original URL, book locator, or source-versioned locator | `NOT_AVAILABLE` | Findings cannot be anchored to an authoritative source |
| Extraction actor, tool, date, and transformation history | `NOT_AVAILABLE` | Provenance and reproducibility remain open |
| Chain of custody | `NOT_AVAILABLE` at authoritative-source level | Source-to-artifact lineage remains open |
| Copyright, license, educational-use, display, and redistribution terms | `NOT_AVAILABLE` | Rights review remains blocked |
| Image/table rights, if applicable | `NOT_AVAILABLE` | Embedded-material rights remain open |
| Professional track and taxonomy evidence | `NOT_SUPPLIED` in the reviewed authority record | Track/taxonomy gate remains open |
| Named reviewer, credentials, review date, decision, and audit event | `NOT_SUPPLIED` | Clinical and technical review cannot be completed |

The internal `SEG_INTERNAL_ASSET` declaration supports controlled project management of the retained artifact. It does not replace source-version tracking, rights review for incorporated material, medical review, technical review, or an auditable review decision.[2]

## 6. Review record requirements

A future review record must identify the exact artifact and SHA-256, the canonical source/version if later established, the reviewer role and authorized identity, the review date/time, exact sections or entities examined, cited source locations, findings, conflicts, unresolved issues, and disposition. Clinical review, Pharmacology/Drug Safety review, technical review, rights review, provenance review, and track/taxonomy review must remain separate streams.

No review record, approval decision, rights clearance, or source-level promotion is created by this document.

## 7. Remaining blockers and next allowed action

The review remains blocked by unresolved canonical source identity/version, provenance, rights, locators, and independent review evidence. The next allowed action is to obtain or document the missing evidence, assign authorized reviewers by role, and conduct separate review against the unchanged exact artifact. The HTML must remain preserved as a read-only evidence item.

The following actions remain prohibited: clinical-content correction, normalization, Content Record creation, schema/database work, import, activation, publication, learner exposure, and any change to Source Registry approval state.

## 8. Governance controls

| Control | Current state |
|---|---|
| Ownership classification | `SEG_INTERNAL_ASSET` for the declared retained artifact |
| Review result | `REVIEW_BLOCKED_PENDING_EVIDENCE` |
| Source approval | `APPROVED_SOURCES = NONE` |
| Normalization | `BLOCKED_PENDING_APPROVED_SOURCE` |
| Medical approval | Not granted |
| Rights approval | Not granted |
| Technical approval | Not granted |
| Artifact modification | Not performed |
| Import/activation/publication | Not performed |

## 9. Final status

`SEG_DRUG_HTML_REVIEW_STATUS_COMPLETE`

This status confirms completion of a review-status preparation record. It does not certify clinical accuracy, drug safety, rights, source identity, version currency, or production readiness.

## References

[1]: file:///home/ubuntu/seg-internship-output/SEG_DRUG_HTML_AUTHORITY_EVIDENCE_RECORD.md "SEG Drug HTML Authority Evidence Record"

[2]: file:///home/ubuntu/seg-internship-output/SEG_INTERNAL_OWNERSHIP_DECLARATION_v1.md "SEG Internal Ownership Declaration v1"

[3]: file:///home/ubuntu/seg-internship-output/SEG_P0_REVIEW_ASSIGNMENT_MATRIX.md "SEG P0 Review Assignment Matrix"

[4]: file:///home/ubuntu/seg-internship-output/SEG_P0_VERSION_CONTROL_REGISTER.md "SEG P0 Version Control Register"

[5]: file:///home/ubuntu/seg-internship-output/SEG_P0_AUDIT_TRAIL_REGISTER.md "SEG P0 Audit Trail Register"

**Document status:** `REVIEW_STATUS_RECORDED_PENDING_INDEPENDENT_CLINICAL_AND_DRUG_SAFETY_REVIEW`
